Vendor, Burlingame, CA
Inflammatix, Inc.
UEI WK9MLMSHBVL3, CAGE 7Q4D9
2 awards and -$1 obligated between January 23, 2024 and March 11, 2026, 100% under full and open competition, against 1.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | -$1 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 2 |
| Definitive Contract | 2 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75A50122C00069Definitive Contract, January 23, 2024, Full and Open Competition, 1 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | Inflammatix, INC. R&D for Triverity Cartridge Development Aoi #2 (Infection Severity and Solving Sepsis)NAICS 541714, PSC AN13 | $0 |
| 75A50119C00034Definitive Contract, September 17, 2025, Full and Open Competition, 1 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | Add Supplemental FundingNAICS 541714, PSC AN42 | -$1 |
- Places of performance
- California
- Product and service codes
- AN13 Health R&D Services; Health Care Services; Experimental DevelopmentAN42 Health R&D Services; Health Care - Other; Applied Research
- Transactions
- 5 across 2 awards